Alpharma: Let board discuss King bid; Genentech hires MIT prof for VP post

> Alpharma exhorted its shareholders not to act on King Pharmaceuticals' hostile bid for the company until the board has considered the higher, $37-per-share offer. Report

> Some on Wall Street are betting that the hot pace of biotech buyouts still has a long way to run. Biotech companies are in control of the future of medicine, with emerging cures for ailments as opposed to treatments for side effects, said one analyst. Report

> Genentech tapped Morgan Sheng to the newly created post of vice president of neuroscience; Sheng had been a professor at the Massachusetts Institute of Technology. Report

> Shares of Allergan shot up 13 percent on the news that Botox worked as a therapy for chronic migraines in a late-stage trial. And based on its analysis from two studies, Allergan says it will go to the FDA next year to file an sBLA for an added approval. Report

> Valeant Pharmaceuticals said Friday it completed the sale of its Eastern and Western European businesses to Meda AB of Sweden. Report

> Myriad Genetics' board of directors is considering a possible spinoff of its core molecular diagnostics business as it undertakes a strategic review of the company's options. Report

> Sun Pharmaceutical Industries received final FDA approval to make and sell alendronate sodium, the generic form of Merck's osteoporosis treatment Fosamax. Report

> French biopharma Stallergenes opened its new production unit near Paris, where it will make allergy desensitization treatments for markets in Europe and North America. Report

> A fresh batch of trial data indicates that the Novartis Meningitis B vaccine protects infants six months and older against multiple strains of potentially deadly meningococcal B bacteria. Report

> A team of top vaccine researchers say that the key to coming up with an effective vaccine to guard against MRSA has been found in the 'sticky glue' the bacteria produces to grow as a biofilm. Report

And Finally... Your brain knows you're about to say Eureka before you do. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.